-

03:32:58 PM

REUN Stock News

REUN - Reunion Neuroscience Inc

09/18/23 7:30 AM

Nasdaq : REUN

clinical triallow float

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration

RHEA-AI

neutral

08/01/23 9:03 AM

Nasdaq : REUN

low float

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion" or the " Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM

RHEA-AI

neutral

07/14/23 4:05 PM

Nasdaq : REUN

low float

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion" or the " Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to

RHEA-AI

neutral

07/13/23 7:30 AM

Nasdaq : REUN

low float

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion" or the “ Company ”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to

RHEA-AI

neutral

06/29/23 7:30 AM

Nasdaq : REUN

earningslow float

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting TORONTO, June

RHEA-AI

neutral

06/01/23 7:30 AM

Nasdaq : REUN

low float

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into

RHEA-AI

neutral

04/25/23 7:35 AM

Nasdaq : REUN

low float

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today

RHEA-AI

neutral

04/25/23 7:30 AM

Nasdaq : REUN

low float

Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today

RHEA-AI

neutral

04/03/23 7:30 AM

Nasdaq : REUN

managementlow float

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Reunion Neuroscience Inc. (NASDAQ:

RHEA-AI

very positive

03/27/23 7:30 AM

Nasdaq : REUN

low float

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and

RHEA-AI

neutral

REUN Data

IndustryOutpatient Mental Health and Substance Abuse Centers
Websitehttps://www.crosswordcybersecurity.com
Security nameReunion Neuroscience Inc
SectorHealth Care and Social Assistance

About Reunion Neuroscience Inc

crossword cybersecurity is a technology commercialisation company focusing exclusively on the cyber security sector. we work with research intensive european university partners to identify promising cyber security intellectual property ("ip") from research that our industry partners tell us meet emerging real-world challenges. our specialist cyber security software engineering team work with our university partners to develop the research concept into a fully fledged commercial product that we bring to market. our first product, rizikon (www.rizikon.io) is a cyber risk analysis and investment prioritisation tool that can help you understand where your biggest vulnerabilities are and how to invest in protecting against them. crossword cybersecurity plc was founded in 2014.